Hikal Ltd Hits New 52-Week Low at Rs. 230 Amid Ongoing Decline

Hikal, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs. 230 today, marking a significant downturn for the stock. This decline comes as the company has underperformed its sector by 1.34% and has experienced a consecutive fall over the past three days, resulting in a total drop of 5.36% during this period. The stock's performance has been notably weak, trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. In the broader market context, the Sensex has also faced challenges, falling by 374.19 points to 82,775.96, reflecting a negative sentiment across the board. Hikal's one-year performance stands at a decline of 38.04%, contrasting sharply with the Sensex's positive return of 4.07%. The company has reported a significant drop in profit after tax, with a quarterly figure of Rs. -22.40 crore, indicating a 198.7% decline compared to the previous four-quarter average. This trend underscores the ongoing difficulties faced by Hikal in both short-term and long-term performance metrics.